Simufilam found safe in review of ongoing Alzheimer's clinical trials
After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue without modification.| Alzheimer's News Today
After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue without modification.| Alzheimer's News Today
BioXcel plans to test BXCL501 for treating agitation in Alzheimer’s disease dementia in patients in nursing and assisted living facilities.| Alzheimer's News Today
Wallowing in self-pity is tempting in the wake of an Alzheimer's diagnosis, but it's crucial to keep moving forward, says columnist Ray Burow.| Alzheimer's News Today
Columnist Ray Burow remembers her recently passed mother-in-law, who remained loving and loved during her short-term memory loss.| Alzheimer's News Today
Biogen is discontinuing development and commercialization of its controversial Alzheimer's treatment Aduhelm to focus its efforts on Leqembi.| Alzheimer's News Today
Simufilam, a small molecule targeting the filamin A protein, is being tested in clinical trials to potentially treat Alzheimer's disease.| Alzheimer's News Today
The new ApoE4 Alzheimer's Alliance plans to advocate on behalf of patients with this gene variant for more supportive U.S. policies.| Alzheimer's News Today
Winter in a cold climate can add challenges when caregiving for someone with dementia, columnist Ray Burow writes.| Alzheimer's News Today
Recruitment has begun at the first clinical site of START, a Phase 2 study evaluating Elayta in adults with early Alzheimer's disease.| Alzheimer's News Today
Anavex is preparing meetings with regulatory authorities in the U.S., Europe, and Asia-Pacific to discuss Anavex 2-73’s potential approval.| Alzheimer's News Today
Alpha Cognition’s oral tablet ALPHA-1062 may be a bioequivalent to galantamine hydrobromide – sold as Razadyne – for Alzheimer’s disease.| Alzheimer's News Today
Marisa Wexler is a senior science writer for Alzheimer's News Today with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Donanemab slowed cognitive, functional ability declines in early Alzheimer’s disease, according to top-line data from a Phase 3 trial.| Alzheimer's News Today
Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic Alzheimer’s.| Alzheimer's News Today
Category archive page for News.| Alzheimer's News Today
The safety and efficacy of buntanetap therapy are comparable in early Alzheimer’s patients regardless of APOE4 status, per new trial data.| Alzheimer's News Today
With the high temperatures expected this summer, columnist Ray Burow recalls tips she used to help loved ones with dementia handle the heat.| Alzheimer's News Today
The Phase 2 study will further assess SNK01's safety and its efficacy in about 30 patients who'll receive it every three weeks up to a year.| Alzheimer's News Today
Eisai is seeking FDA approval of a monthly maintenance IV regimen of Leqembi for people with early Alzheimer’s disease.| Alzheimer's News Today
